48
Participants
Start Date
February 28, 2006
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
5-Fluorouracil
5-FU bolus was administered at 400mg/m\^2 on day 1 and day 2 of each cycle. 5-FU at 600 mg/m\^2 infusion was administered over 22 hours on day 1 and day 2 of each cycle.
Leucovorin (LV)
Leucovorin 200mg/m\^2 was administered over 2 hours on day 1 and day 2 of each cycle.
Gamma-Interferon-1b (IFN-γ)
Gamma-Interferon 150 mcg/m\^2 was administered by subcutaneous injection on day 1 of each cycle immediately before treatment with 5-FU and LV, and on day 3 of each cycle immediately after treatment with 5-FU and LV.
Bevacizumab
Bevacizumab 5mg/kg was only added to the treatment regimen of patients in stratum 1 who demonstrated stable disease on imaging repeated prior to the 5th cycle of treatment. Bavacizumab was administered on day 4 of each cycle.
The West Clinic, Memphis
Collaborators (1)
InterMune
INDUSTRY
Accelerated Community Oncology Research Network
OTHER